Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (17) ·
''Mimosa tenuiflora''. Jurema preta, tepescohuite (1) ·
''Sophora secundiflora''. Texas mountain laurel, frijolillo (1) ·
Clozaril (1) ·
DXM (1) ·
DXO (1) ·
Fanapt (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Orap (1) ·
Prolixin (1) ·
Reed canary grass (1) ·
Saphris (1) ·
Sonoran Desert Toad, Colorado River Toad (1) ·
Spravato (1) ·
Stelazine (1) ·
The ayahuasca vine, ''yagé'', ''caapi'', ''mariri'' (1) ·
Thorazine (1) ·
Trilafon (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
5-MeO-DMT is a potent 5-HT1A agonist (greater than 5-HT2A). Distinct from N,N-DMT in producing a more unitive, less visual, often ego-dissolving experience. (1) ·
Active alkaloid is cytisine, a nicotinic acetylcholine receptor agonist. NOT a classical 5-HT2A psychedelic. (1) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Butyrophenone D2 antagonist (1) ·
Contains salvinorin A (1) ·
Contains the β-carboline alkaloids harmine, harmaline, and tetrahydroharmine, reversible monoamine oxidase inhibitors (RIMAs) that allow oral DMT to reach the brain. (1) ·
Contains varying amounts of DMT, 5-MeO-DMT, bufotenine, and gramine depending on strain and growing conditions. (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Multi-receptor antagonist; low D2 affinity (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Phenothiazine D2 antagonist (4) ·
Root bark contains ~1% N,N-dimethyltryptamine (DMT) and related tryptamines. Oral activity requires MAOI co-administration. (1) ·
Thioxanthene D2 antagonist (1)
uses:
None (35) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-00000006-QINU`"' (3) ·
'"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"' (2)
starting dose:
preparations:
None (35) ·
28 mg/device (each dose uses 2 devices) (1) ·
Acid/base extraction of fresh young grass for tryptamines; combined with an MAOI (1) ·
Bark/woody stem decocted with a DMT-source plant (''Psychotria viridis'', ''Diplopterys cabrerana'') to make ayahuasca (1) ·
Bright red seeds, traditionally ingested or smoked. Highly toxic, narrow margin between active and lethal (1) ·
Parotid-gland venom expressed onto a glass plate, dried into a shellac-like resin, vaporized and inhaled (1) ·
Root bark acid/base-extracted for DMT; or as the resurrected ''jurema preta'' brew (decocted with an MAOI such as ''Peganum harmala'') (1)
fda max:
routes:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 41 results in range #1 to #41.